

45. Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Leger JM et al. Characterization of cryoglobulins by immunoblotting. *Clin Chem.* 1992;38(6):798-802.
46. Sargur R, White P, Egner W. Cryoglobulin evaluation: best practice? *Ann Clin Biochem.* 2010;47:8-16.
47. Vermeersch P, Gijbels K, Mariën G, Lunn R, Egner W, White P, Bossuyt X. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. *Clin Chem.* 2008;54(1):39-43.
48. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Semin Oncol.* 2003;30(2):110-115.
49. Gerz MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. *Amer J Hematol.* 2021;96(2):258-269.
50. Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia.* 2018;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7.
51. Elba S, Castellino A, Soriasio R, et al. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. *J Med Case Rep.* 2020;14(1):75. doi: 10.1186/s13256-020-02380-2.
52. Jelínek T, Bezděková R, Zátoková M, et al. Current applications of multiparameter flow cytometry in plasma cell disorders. *Blood Cancer J.* 2017;7(10):e17. doi: 10.1038/bcj.2017.90.
53. Wang W, Lin P. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis. *Pathology.* 2020;52(1):6-14. doi: 10.1016/j.pathol.2019.09.009.
54. Baďurová K, Gregorová J, Vlachová M, et al. Waldenströmova makroglobulinémie. *Klin. onkol.* 2021;34(6):428-433.
55. Sedlářiková L, Sadilíková K, Bešše L, et al. Cytokinové profily mnohočetného myelomu a Waldenströmovy makroglobulinémie. *Klin. Onkol.* 2014;27(1):18-23.
56. Growková K, Chyza Z, Jelínek T, et al. Diagnostic tools of Waldenström's macroglobulinemia – best possibilities for non-invasive and long-term disease monitoring. *Klin. onkol.* 2017;30(Suppl. 2):81-91.
57. Kutáľková K, Sedlářiková L, Ševčíková S, et al. Genetické změny u Waldenströmovy makroglobulinémie. *Vnitř. Lék.* 2016;62(1):40-43.
58. Ševčíková S, Novák L, Bešše L, et al. Molekulární podstata Waldenströmovy makroglobulinémie. *Klin. onkol.* 2012;25(6):413-420.
59. Ranjit Banwait, Kevin O'Regan, Federico Campigotto, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. *American J. Hematology.* 2011;86(7):567-572. <https://doi.org/10.1002/ajh.22044>.
60. Kaščák M, Hájek R, Minařík J, et al. Diagnostika a léčba Waldenströmovy makroglobulinémie. *Transfuzie a Hematologie dnes.* 2022;28(Suppl.1):S44-S74.
61. Leleu X, Xie W, Bagshaw M, Banwait R. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. *Clin Cancer Res.* 2011;17(9):3013-3018. doi: 10.1158/1078-0432.CCR-10-2954.
62. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. *Leuk Lymphoma.* 2008;49(6):1104-1107. doi: 10.1080/10428190802074619.
63. Itzykson R, Le Garff-Tavernier M, Katsahian S, et al. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. *Haematologica.* 2008;93(5):793-794. doi: 10.3324/haematol.12107.
64. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. *Lancet Haematol.* 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6.
65. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. *Br J Haematol.* 2000;108:737-742.
66. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. *J Clin Oncol.* 2013;31:301-307.
67. Souchet L, Levy V, Ouzegdouh M, et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. *Am J Hematol.* 2016;91:782-786.
68. Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, et al. Response rate to the treatment of Waldenstrom macroglobulinemia: a meta-analysis of the results of clinical trials. *Crit Rev Oncol Hematol.* 2016;105:118-126.
69. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. *Curr Opin Neurol.* 2009;22:480-485.
70. Lunn MP. Neuropathies and paraproteins. *Curr Opin Neurol.* 2019;32(5):658-665. doi: 10.1097/WCO.0000000000000726.
71. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. *Cancer.* 2004;101:2593-2598.
72. Rummel MJ, Lerchenmüller C, Hensel M, et al. Two years rituximab maintenance vs. observation after first line treatment with Bendamustine Plus Rituximab (B-R) in patients with Waldenström's Macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study. *Blood.* 2019;134:343-343.
73. Dimopoulos MA, Anagnostopoulos A, Kyrtonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. *J Clin Oncol.* 2007;25:3344-3349.
74. Kastritis E, Gavriatopoulou M, Kyrtonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. *Blood.* 2015;126:1392-1394.
75. Mössner E, Brünker P, Moser P, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new Type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. *Blood.* 2010;115(22):4393-4402.
76. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood.* 2016;128(10):1321-1328.
77. Gavriatopoulou M, Kastritis E, Kyrtonis MC, et al. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. *Leuk Lymphoma.* 2017;58(6):1506-1508.
78. Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. *Lancet Haematol.* 2017;4(1):e24-e34.
79. Buske C. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia? *Lancet Haematol.* 2017;4(1):e4-e5.
80. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. *Mol Cancer Ther.* 2013;12(10):2031-2042.
81. Adam Z, Krejčí M, Pour L, et al. Obinutuzumab v léčbě pacientů s Waldenströmovou makroglobulinémií netolerující rituximab – popis případu *Transfuzie a hematologie dnes.* 2021;27(2):160-165.
82. Tomowiak C, Poulain S, Herbaux C, et al. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. *Blood Adv.* 2021;5(9):2438-2446. doi: 10.1182/bloodadvances.2020003895.
83. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma Leuk.* 2011;11:133-135.
84. Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. *Leuk Lymphoma.* 2015;56:2637-2642.
85. Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). *Br J Haematol.* 2019;186:146-149.
86. Rummel MJ, Lerchenmüller C, Hensel M, et al. Two years rituximab maintenance vs. observation after first line treatment with Bendamustine Plus Rituximab (B-R) in patients with Waldenström's Macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7-2008 MAINTAIN trial). *Blood.* 2019;134:343-343.
87. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet.* 2013;381:1203-1210.
88. Castillo JJ, Gustine J, Meid K, et al. Bendamustine and bortezomib-containing regimens produce higher response rates and more durable responses versus cyclophosphamide-based therapy in frontline Waldenstrom macroglobulinemia. *Blood.* 2017;130(Suppl.1):1488-1489.
89. Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. *Ann Hematol.* 2018;97:1417-1425.
90. Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, et al. Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. *Crit Rev Oncol Hematol.* 2016;105:118-126. doi: 10.1016/j.critrevonc.2016.06.004.
91. Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. *Blood.* 2019;133:299-305.
92. Benevolo G, Ferrero S, Villivà N, et al. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). *Blood.* 2021;138(Supplement 1):48. doi: <https://doi.org/424>.
93. Chan WLW, Chong VCL, et al. Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis. *Blood.* 2021;138(Supplement 1):1358. doi: <https://doi.org/10.1182/blood-2021-150678>.
94. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. *Blood.* 2008;112:4452-4457.
95. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. *Clin Cancer Res.* 2009;15(1):355-360. doi:10.1158/1078-0432.CCR-08-0862.
96. Fouquet G, Guidez S, Petillon MO, et al. Lenalidomide is safe and active in Waldenströmmacroglobulinemia. *Am J Hematol.* 2015;90(11):1055-1059. doi: 10.1002/ajh.24175.
97. Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia. *Clin Lymphoma Myeloma Leuk.* 2010;10:110-117.
98. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk.* 2013;13(2):235-237. doi: 10.1016/j.clml.2013.02.014.
99. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. *J Clin Oncol.* 2009;27:3830-3835.